- Home
- LU vs INBX Comparison
LU vs INBX Comparison
Compare LU & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | INBX |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | LU | INBX |
|---|---|---|
| Price | $1.35 | $94.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 1.3M | 278.6K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $1.29 | $13.97 |
| 52 Week High | $4.57 | $155.29 |
Technical Indicators
Market Signals| Indicator | LU | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 22.77 | 44.18 |
| Support Level | N/A | $71.31 |
| Resistance Level | $2.77 | $94.52 |
| Average True Range (ATR) | 0.08 | 6.81 |
| MACD | -0.02 | -1.05 |
| Stochastic Oscillator | 14.44 | 37.90 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.